Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

Insiders have been trading these 5 stocks: (($ASX)), (($PRQR)), (($ABSI)), (($RARE)) and (($YPF)). Here is a breakdown of their recent trades and t...

ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on AbSci, with a price target of $16.00. Ramakanth ...

AbSci (ABSI) Receives a Buy from H.C. Wainwright

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Annexon Biosciences (ANNX), AbSci (ABSI) and Omnicel...

Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), AbSci (ABSI) and Omnicell (OMCL)

BTIG analyst Kambiz Yazdi maintained a Buy rating on AbSci today and set a price target of $13.00. According to TipRanks, Yazdi is a 5-star analyst...

BTIG Remains a Buy on AbSci (ABSI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Diamedica Therapeutics (DMAC), Revolution Medicines ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

AbSci ( ($ABSI) ) has provided an update. On June 24, 2026, Absci priced an underwritten public offering of 13,495,277 shares of common stock at $7...

Absci Announces $100 Million Public Equity Offering

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD) and AbSci (ABSI). InMode (INMD) In a...

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD) and AbSci (ABSI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inmune Bio (INMB), AbSci (ABSI) and Ionis Pharmaceut...

Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)

AbSci ( ($ABSI) ) has shared an update. On June 24, 2026, Absci reported positive interim Phase 1 data from its first-in-human HEADLINE trial of AB...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABSI	$10.60	-7.59%	4.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABSI	$10.60	-7.6%	4.70M
3
4
5
6

ABSI

ABSI

Get Absci Corporation Data in Excel

Get Absci Corporation Data in Excel